F007 The Morbilliform Eruption: Differentiation and Treatment of Viral, Low-Risk Drug, Severe Cutaneous Adverse Reactions, and GVHD
DESCRIPTION
The morbilliform eruption is the most common cutaneous morphology encountered in the hospital setting. Despite its frequency, there is a dearth of literature and lectureships available to support evidenced-based guidelines especially for evaluation of the undifferentiated patient. This session will focus on the early and accurate diagnosis and differentiation of low-risk drug eruptions, severe cutaneous adverse reactions, viral eruptions, and GVHD in the adult patient.
LEARNING OBJECTIVES
Identify distinguishing characteristics that allow differentiation of morbilliform eruptions into high-risk and low-risk categories
Differentiate early severe cutaneous adverse reactions by morphologic differences, followed by confirmatory testing
Recognize laboratory testing and algorithms available to support the diagnosis of drug eruptions, viral reactions, and Graft-Versus-Host Disease.
DIRECTOR
Benjamin Kaffenberger, MD, MS, FAAD
Ohio State university
DISCLOSURES
Benjamin Kaffenberger, MD, MS, FAAD
Almirall – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant (1099 relationship)(Honoraria); HCW Biologics – Investigator(Grants/Research Funding); InflaRx – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); Leo Pharma – Investigator(Grants/Research Funding); National Comprehensive Cancer Network – Speaker(Honoraria); Pfizer Inc. – Data Safety Monitoring Board(Fees); Protillion Biosciences – Consultant (1099 relationship)(Stock Options);